Alcon today announced the launch of ILEVRO™ Suspension, a new once-daily treatment option for pain and inflammation associated with cataract surgery. In two double masked, randomized clinical trials, ILEVRO™ Suspension demonstrated superior clinical efficacy compared to its vehicle.